(Sharecast News) – Hikma Pharmaceuticals lifted annual revenue and margin guidance for its generics business as first-half core operating profit rose 35%.
The drugmaker on Thursday said it now expected the generics business to report revenue growth of close to 30%, up from its previous forecasts of around 20%, and core operating margin to be 18 – 20%, up from 16 – 18%.

Core operating profit came in at $401m from $296m a year ago. Revenue was up 18% to $1.4bn.

“Our generics business had an excellent first half, as the competitive pressures experienced in 2022 began to ease. We have seen a reduction in price erosion and we have been able to increase volumes across the portfolio,” the company said.

Reporting by Frank Prenesti for Sharecast.com

Related articles

Full-year profits slide at Close Brothers

Full-year profits slide at Close Brothers

(Sharecast News) - Close Brothers Group reported a decline in its full-year statutory operating profit before tax on Tuesday, to £112m from 2022's £232.8m. The FTSE 250 company said that figure included provisions of £114.6m related to Novitas, which it disclosed in...

Latest Articles

Asia report: Markets fall as Japan’s wholesale inflation rises

Asia report: Markets fall as Japan’s wholesale inflation rises

(Sharecast News) - Asia-Pacific markets experienced a downturn on Tuesday despite a broad rebound on Wall Street overnight. Contributing to the cautious mood in the region was new data from Japan indicating that wholesale inflation surged at its fastest rate in nearly...

Full-year profits slide at Close Brothers

Full-year profits slide at Close Brothers

(Sharecast News) - Close Brothers Group reported a decline in its full-year statutory operating profit before tax on Tuesday, to £112m from 2022's £232.8m. The FTSE 250 company said that figure included provisions of £114.6m related to Novitas, which it disclosed in...

Join our mailing list

Subscribe to our mailing list to receive regular updates!

No Fields Found.
x